Search

Publications

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Read more

Thrombocytopenias and Platelet Function Disorders

The SWG was established at the 2003 EHA Congress, which was held in Lyon, France. The group's original focus was thrombocytopenias, but it subsequently expanded its field of interest with the inclusion of platelet function disorders.

Read more

Access

Improving affordable and equal access to innovative therapies in hematology for patients across Europe is EHA’s overriding advocacy priority.

Read more

YoungEHA Webinar on Burnouts: When caregivers become patients - talking about awareness

In order to create awareness for burnout symptoms among hematologists, the YoungEHA Committee has planned a webinar on burnouts to help professionals in hematology identify early signs and how to address this issue in a wider context.

Read more

About us

The European Hematology Association (EHA): “Towards prevention, cure, and quality of life for all patients with blood disorders”.

Read more

Horizon 2020: The European Commission proposes the successor to Framework Programme 7

Horizons 2020 will pay “particular attention to ensuring a broad approach to innovation, which is not only limited to the development of new products and services on the basis of scientific and technological breakthroughs, but which also incorporates aspects such…

Read more

HemaSphere, the Official Journal of the European Hematology Association, Receives Its First Impact Factor

The Hague, June 2022 - HemaSphere, the official peer-reviewed journal of the European Hematology Association (EHA), has received its first Journal Impact Factor™. The preliminary 2021 Journal Impact Factor for HemaSphere is 8.

Read more

A European Reference Network for Rare Hematological Diseases

You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.

Read more